📄 Entero Therapeutics, Inc.

📄 Entero Therapeutics, Inc. Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted, non-systemic therapies for gastrointestinal diseases. Its lead program is Adrulipase, a recombinant lipase enzyme for treating exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients. The company has discontinued prior programs and is in the process of rescinding a merger with ImmunogenX, LLC. Offering: $3,025,000 at $3,025,000 valuation Key risk: Substantial doubt about ability to continue as a going concern due to recurring losses and dependency on external funding. Proceeds: General working capital purposes Lockup: 90 days

Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted, non-systemic therapies for gastrointestinal diseases. Its lead program is Adrulipase, a recombinant lipase enzyme for treating exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients. The company has discontinued prior programs and is in the process of rescinding a merger with ImmunogenX, LLC.